1. Home
  2. CGEN vs GLU Comparison

CGEN vs GLU Comparison

Compare CGEN & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • GLU
  • Stock Information
  • Founded
  • CGEN 1993
  • GLU 2004
  • Country
  • CGEN Israel
  • GLU United States
  • Employees
  • CGEN N/A
  • GLU N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • GLU Finance/Investors Services
  • Sector
  • CGEN Health Care
  • GLU Finance
  • Exchange
  • CGEN Nasdaq
  • GLU Nasdaq
  • Market Cap
  • CGEN 117.8M
  • GLU 99.4M
  • IPO Year
  • CGEN 2000
  • GLU N/A
  • Fundamental
  • Price
  • CGEN $1.47
  • GLU $16.71
  • Analyst Decision
  • CGEN Strong Buy
  • GLU
  • Analyst Count
  • CGEN 1
  • GLU 0
  • Target Price
  • CGEN $4.00
  • GLU N/A
  • AVG Volume (30 Days)
  • CGEN 216.5K
  • GLU 12.4K
  • Earning Date
  • CGEN 05-19-2025
  • GLU 01-01-0001
  • Dividend Yield
  • CGEN N/A
  • GLU 8.60%
  • EPS Growth
  • CGEN N/A
  • GLU N/A
  • EPS
  • CGEN N/A
  • GLU 0.62
  • Revenue
  • CGEN $27,589,000.00
  • GLU N/A
  • Revenue This Year
  • CGEN $11.81
  • GLU N/A
  • Revenue Next Year
  • CGEN $28.37
  • GLU N/A
  • P/E Ratio
  • CGEN N/A
  • GLU $22.50
  • Revenue Growth
  • CGEN N/A
  • GLU N/A
  • 52 Week Low
  • CGEN $1.13
  • GLU $11.61
  • 52 Week High
  • CGEN $2.66
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 53.98
  • GLU 56.90
  • Support Level
  • CGEN $1.38
  • GLU $16.53
  • Resistance Level
  • CGEN $1.56
  • GLU $16.99
  • Average True Range (ATR)
  • CGEN 0.08
  • GLU 0.33
  • MACD
  • CGEN 0.02
  • GLU -0.04
  • Stochastic Oscillator
  • CGEN 68.97
  • GLU 52.78

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: